Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AVB-S6-500 with Paclitaxel and Carboplatin in Ovarian Cancer
NCT03607955Phase 1Withdrawn
- Sponsor
- Washington University School of Medicine
- Start
- Jun 2021
- Primary completion
- Aug 2024
- Modality
- Fc-Fusion Proteins
01
Overview
Phase 1, open-label, single-arm trial of batiraxcept in epithelial ovarian cancer (EOC), primary peritoneal carcinoma (PPC) and fallopian tube cancer (PFTC), sponsored by Washington University School of Medicine. Primary endpoints: Maximum Tolerated Dose at 26 months, Dose Limiting Toxicities at 13 months and 5 more. Planned start Jun 2021; status: withdrawn.
02
Drugs
batiraxcept
03
Conditions
epithelial ovarian cancer (EOC)primary peritoneal carcinoma (PPC)fallopian tube cancer (PFTC)
Beyond the preview
Go deeper on NCT03607955.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03607955.